Business Segments · Integration-related cost, expense
Oncology & Multispecialty — Integration-related cost, expense
McKesson Oncology & Multispecialty — Integration-related cost, expense remained flat by 0.0% to $24.00M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2026
Last reportedQ4 2026May 8, 2026
Rolls up toAcquisition and integration costs
How to read this metric
High costs are expected following acquisitions, but sustained high levels may indicate integration difficulties or poor synergy realization.
Detailed definition
Costs incurred to integrate newly acquired businesses into the existing oncology and multispecialty operations. These in...
Peer comparison
Standard disclosure for companies with active M&A strategies.
Metric ID:
mck_segment_oncology_multispecialty_integration_related_cost_expenseHistorical Data
1 years
| FY'26 | |
|---|---|
| Value | $96.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — integration-related cost, expense?
- McKesson (MCK) reported oncology & multispecialty — integration-related cost, expense of $24.00M in Q1 2026.
- What does oncology & multispecialty — integration-related cost, expense mean?
- Costs associated with merging new acquisitions into the company.